Bookmark and Share

BioActivity Data for Gene LYPLA2 (Gene ID:11313)

Also known as: RP5-886K2.5, APT-2, DJ886K2.4.
BioActivity Outcomes:
Active(77)
 
 
Inactive(209)
 
 
Unspecified(6)
 
 
BioAssay Types:
Confirmatory(19)
 
 
 
 
Literature(5)
 
 
 
Screening(4)
 
 
BioActivity Types:
IC50(8)
 
 
 
 
Ki(3)
 
 
 
Substance Types:
Chemical(281)
 
 
 
 
RNAi(11)
 
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 25    Data Row: 292   Total Pages: 15   Display: Page     
Sort: [Click the result table header to sort]
#StructureSubstanceCompoundActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID194168343]
[CID56641205]
IC50 0.0196Inhibition of APT2 (unknown origin) [AID1079562, Type: confirmatory] [gi:41017276]
View
2
[SID194134364]
[CID56593118]
IC50 0.03Inhibition of human APT2 [AID1079559, Type: confirmatory] [gi:41017276]
View
3
[SID164117611]
[CID71710938]
0.143Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in situ [AID743119_2, Type: confirmatory] [gi:9966764]
View
4
[SID160654496]
[CID16193817]
0.144Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP [AID651990_2, Type: confirmatory] [gi:9966764]
View
5
[SID194175173]
[CID56593111]
IC50 0.2Inhibition of human APT2 [AID1079559, Type: confirmatory] [gi:41017276]
View
6
[SID164117614]
[CID71710927]
0.217Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_2, Type: confirmatory] [gi:9966764]
View
7
[SID194147952]
[CID16193817]
Ki 0.23Inhibition of APT2 (unknown origin) by FluPol-ABPP assay [AID1079555, Type: confirmatory] [gi:41017276]
View
8
[SID164117611]
[CID71710938]
0.245Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_2, Type: confirmatory] [gi:9966764]
View
9
[SID164117604]
[CID71710942]
0.258Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_2, Type: confirmatory] [gi:9966764]
View
10
[SID164117610]
[CID71710929]
0.384Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_2, Type: confirmatory] [gi:9966764]
View
11
[SID164117613]
[CID71710939]
0.726Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical dose-response gel-based ABPP in vitro [AID743118_2, Type: confirmatory] [gi:9966764]
View
12
[SID194175172]
[CID16742753]
Ki 0.73Inhibition of APT2 (unknown origin) by enzyme kinetic assay [AID1079560, Type: confirmatory] [gi:41017276]
View
13
[SID164117611]
[CID71710938]
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding mode [AID743133_1, Type: other] [gi:9966764]
View
14
[SID164117611]
[CID71710938]
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: Fluorescence-based biochemical gel-based ABPP gel filtration assay to assess inhibitor binding mode [AID743133_2, Type: other] [gi:9966764]
View
15
[SID164117611]
[CID71710938]
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis [AID743137_2, Type: other] [gi:9966764]
View
16
[SID160709332]
[CID70697687]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_2, Type: other] [gi:9966764]
View
17
[SID160709335]
[CID70697702]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_2, Type: other] [gi:9966764]
View
18
[SID92709352]
[CID24792060]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: Fluorescence-based biochemical gel-based ABPP inhibition [AID652029, Type: other] [gi:9966764]
View
19
[SID160709325]
[CID70697710]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_2, Type: other] [gi:9966764]
View
20
[SID160709328]
[CID70697696]
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in vitro, Set 2 [AID652018_2, Type: other] [gi:9966764]
View